Literature DB >> 20620709

Risk factors for venous thromboembolism.

Samuel Z Goldhaber1.   

Abstract

Risk factors for venous thromboembolism (VTE) are often modifiable and overlap with risk factors for coronary artery disease. Encouraging our patients to adopt a heart-healthy lifestyle by abstaining from cigarettes, maintaining lean weight, limiting red meat intake, and controlling hypertension might lower the risk of pulmonary embolism and deep vein thrombosis (DVT), although a cause-effect relationship has not been firmly established. For hospitalized patients, guidelines have provided evidence-based strategies to identify patients at risk, such as elderly persons and those with cancer, congestive heart failure, or chronic obstructive pulmonary disease or undergoing major surgery. Most should receive pharmacological prophylaxis, which will minimize the risk of VTE. Because approximately 3 of every 4 pulmonary embolism and DVT events occur outside the hospital setting, patients should also be assessed for persistent high-risk of VTE at the time of hospital discharge. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20620709     DOI: 10.1016/j.jacc.2010.01.057

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  88 in total

1.  Venous thrombosis at altitude presents with distinct biochemical profiles: a comparative study from the Himalayas to the plains.

Authors:  Amit Prabhakar; Tathagata Chatterjee; Nitin Bajaj; Tarun Tyagi; Anita Sahu; Neha Gupta; Babita Kumari; Velu Nair; Bhuvnesh Kumar; Mohammad Zahid Ashraf
Journal:  Blood Adv       Date:  2019-11-26

2.  Circulating ceruloplasmin, ceruloplasmin-associated genes and the incidence of venous thromboembolism in the Atherosclerosis Risk in Communities study.

Authors:  Antonio P Arenas de Larriva; Alvaro Alonso; Faye L Norby; Nicholas S Roetker; Aaron R Folsom
Journal:  J Thromb Haemost       Date:  2019-03-18       Impact factor: 5.824

3.  Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans.

Authors:  W Hernandez; E R Gamazon; K Aquino-Michaels; S Patel; T J O'Brien; A F Harralson; R A Kittles; A Barbour; M Tuck; S D McIntosh; J N Douglas; D Nicolae; L H Cavallari; M A Perera
Journal:  Pharmacogenomics J       Date:  2013-09-10       Impact factor: 3.550

4.  Venous thromboembolism in COPD hospitalized patients.

Authors:  Raquel Barba; Antonio Zapatero; Javier Marco; Juan E Losa; Susana Plaza; Jose Manuel Casas; Jesús Canora
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

5.  Approach to smoking cessation in the patient with vascular disease.

Authors:  Elizabeth V Ratchford; James H Black
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-04

Review 6.  Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians.

Authors:  Eduardo Vazquez-Garza; Carlos Jerjes-Sanchez; Aline Navarrete; Jorge Joya-Harrison; David Rodriguez
Journal:  J Thromb Thrombolysis       Date:  2017-10       Impact factor: 2.300

7.  Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population.

Authors:  Nadia Arshad; Trond Isaksen; John-Bjarne Hansen; Sigrid K Brækkan
Journal:  Eur J Epidemiol       Date:  2017-03-17       Impact factor: 8.082

8.  Blood transfusions increase the risk of venous thromboembolism following ventral hernia repair.

Authors:  J H Helm; M C Helm; T L Kindel; J C Gould; R M Higgins
Journal:  Hernia       Date:  2019-03-28       Impact factor: 4.739

9.  Study of clinical profile and management of patients with pulmonary embolism - single center study.

Authors:  S Calwin Davidsingh; Narayanan Srinivasan; P Balaji; U Kalaichelvan; Ajit Sankaradas Mullasari
Journal:  Indian Heart J       Date:  2014-02-01

10.  Elevated serum amyloid A is associated with venous thromboembolism.

Authors:  Hiroshi Deguchi; Darlene J Elias; Silvia Navarro; Francisco España; John H Griffin
Journal:  Thromb Haemost       Date:  2012-12-20       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.